Replies to post #15595 on Mast Therapeutics, Inc. (MSTX)

[someconcerns]

Rather than my throwing numbers out there, why not look at some of the articles and blogposts Leny Hettmansperger has put out over on Seeking Alpha. The most recent one I have is: http://seekingalpha.com/instablog/44479986-leny-hettmansperger/4955333-inexpensive-stock-star-portfolio-plx-63c-mstx-13c-wstl-65c-amrs-45c-xtnt-35c-cbio-50c?app=1&uprof=44&isDirectRoadblock=false

This one covers several stocks but a number of his but others focus on just MSTX. The link to his list of blogposts: http://seekingalpha.com/author/leny-hettmansperger/instablogs

That said, I think he was propounding the thesis that the stock will rise to $.30 or so before the reverse split. I sure don't know what the ratio in the r/s will be, but it will have to be high enough to support uplisting the shares.

After the R/S, he was estimating the shares would grow sharply, once MSTX management is let go and the company is renamed Savara. They have two phase 2 studies ongoing on different drugs, a great relationship with the CF Foundation (which has provided non-dilutive funding) and a coorperative working relationship with the FDA.

I came into this as a long-time Savara shareholder (private as of now) with confidence in Savara management.